T2 Biosystems, Inc.
TTOOHealthcare · Healthcare · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2M | $22.3M | $28.1M | $18.1M | $8.3M | $2.3M |
| Operating income | −$49.7M | −$55.2M | −$43.0M | −$41.4M | −$52.1M | −$11.4M |
| Net income | −$50.1M | −$62.0M | −$49.2M | −$46.8M | −$59.0M | −$12.9M |
| Total assets | $34.8M | $34.3M | $60.5M | $79.1M | $28.5M | $64.3M |
| Total liabilities | $62.8M | $74.0M | $73.4M | — | — | — |
| Equity | −$28.0M | −$39.7M | −$12.9M | $8.7M | −$34.0M | $11.4M |
| EPS (diluted) | $-19.19 | $-1222.14 | $-15.50 | — | — | — |
| Shares out. | 20.3M | 171.0M | 148.5M | 100.8M | 44.3M | 36.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −690.4%
- Net margin
- −696.2%
- Return on equity
- 178.6%
- Return on assets
- −143.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 180.6%
- Debt / equity
- —
- Book value / share
- $-1.38
- Revenue growth (YoY)
- −67.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -70.64distress
- Accruals / assets
- −5.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2023
- NT 10-Qmissed a reporting deadline ↗May 15, 2023
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2022
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2019
- NT 10-Kmissed a reporting deadline ↗Mar 19, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Jsaf Holdings, LlcPassive (13G)Feb 13, 2025
- Safier JacobPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Elsbree David BDirector | Sep 13, 2024 | Sell | 55 | $2.42 |
| Cr Group L.P.10% owner | May 9, 2024 | Conversion | 1.7M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4,939 | 1.3 | 0.0% |
| Apr 30, 2026 | 4,939 | 1.0 | +0.1% |
| Apr 15, 2026 | 4,936 | 1.0 | 0.0% |
| Mar 31, 2026 | 4,936 | 1.0 | 0.0% |
| Mar 13, 2026 | 4,936 | 3.5 | +0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 7, 2025
- Other material eventFeb 20, 2025
- Costs from exit or disposal · Director / officer change · Other material eventFeb 14, 2025
- Delisting / listing-standard noticeFeb 11, 2025
- Entered a material agreementJan 17, 2025
- Results of operations · Other material eventJan 7, 2025
- Director / officer change · Shareholder voteJan 3, 2025
- Delisting / listing-standard noticeDec 13, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.